

Lawrence B Afrin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8880581/publications.pdf>

Version: 2024-02-01

59
papers

1,435
citations

430442

18
h-index

344852

36
g-index

59
all docs

59
docs citations

59
times ranked

1400
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 $\times 10^9$ /L). <i>Journal of Clinical Oncology</i> , 2022, 22, 336-346.	0.2	5
2	Restless legs syndrome is associated with long-COVID in women. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 1413-1418.	1.4	12
3	Post-HPV-Vaccination Mast Cell Activation Syndrome: Possible Vaccine-Triggered Escalation of Undiagnosed Pre-Existing Mast Cell Disease?. <i>Vaccines</i> , 2022, 10, 127.	2.1	3
4	Evaluation of a tryptase depletion index for better pathologic identification of mast cell activation syndrome. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, , .	0.2	0
5	Mast Cell Activation Syndrome: A Primer for the Gastroenterologist. <i>Digestive Diseases and Sciences</i> , 2021, 66, 965-982.	1.1	32
6	Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8960.	1.8	11
7	Mast cell activation symptoms are prevalent in Long-COVID. <i>International Journal of Infectious Diseases</i> , 2021, 112, 217-226.	1.5	85
8	Diagnosis of mast cell activation syndrome: a global $\text{\textcircled{c}}$ consensus-2 $\text{\textcircled{c}}$. <i>Diagnosis</i> , 2021, 8, 137-152.	1.2	59
9	Some cases of hypermobile $\text{\textless scp\textgreater}$ Ehlers $\text{\textless scp\textgreater}$ Danlos syndrome may be rooted in mast cell activation syndrome. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2021, 187, 466-472.	0.7	5
10	Mast cell activation may explain many cases of chemical intolerance. <i>Environmental Sciences Europe</i> , 2021, 33, .	2.6	16
11	Restless legs syndrome is associated with mast cell activation syndrome. <i>Journal of Clinical Sleep Medicine</i> , 2020, 16, 401-408.	1.4	12
12	Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. <i>International Journal of Infectious Diseases</i> , 2020, 100, 327-332.	1.5	219
13	Mast cell activation syndrome in pregnancy, delivery, postpartum and lactation: a narrative review. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 889-901.	0.4	6
14	Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 664-669.	0.4	12
15	Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome. <i>American Journal of the Medical Sciences</i> , 2019, 357, 507-511.	0.4	13
16	Small Intestinal Bacterial Overgrowth Is Common in Mast Cell Activation Syndrome. <i>American Journal of Gastroenterology</i> , 2019, 114, S671-S671.	0.2	2
17	Response to: $\text{\textcircled{c}}$ reply to: $\text{\textcircled{c}}$ Mast Cell Disorders in Ehlers $\text{\textless scp\textgreater}$ Danlos Syndrome $\text{\textcircled{c}}$ ™ (Jaime Vengoechea,) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> , 2019, 176, 251-252.	0.7	2
18	Mast cell deposition and activation may be a new explanation for epiploic appendagitis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224689.	0.2	4

#	ARTICLE	IF	CITATIONS
19	The Significance of Mast Cell Activation in the Era of Precision Medicine. American Journal of Gastroenterology, 2018, 113, 1725-1726.	0.2	2
20	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet, The, 2017, 389, 612-620.	6.3	95
21	Characterization of Mast Cell Activation Syndrome. American Journal of the Medical Sciences, 2017, 353, 207-215.	0.4	65
22	Mast cell disorders in Ehlers-Danlos syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2017, 175, 226-236.	0.7	76
23	Successful targeted treatment of mast cell activation syndrome with tofacitinib. European Journal of Haematology, 2017, 99, 190-193.	1.1	10
24	Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. F1000Research, 2017, 6, 1889.	0.8	35
25	Case Report: Treatment of systemic mastocytosis with sunitinib. F1000Research, 2017, 6, 2182.	0.8	4
26	Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 671-694.	1.4	53
27	Mast cell activation disease and the modern epidemic of chronic inflammatory disease. Translational Research, 2016, 174, 33-59.	2.2	28
28	Often seen, rarely recognized: mast cell activation disease – a guide to diagnosis and therapeutic options. Annals of Medicine, 2016, 48, 190-201.	1.5	51
29	A new era for an old cell: heightened appreciation of mast cell disease emerges. Translational Research, 2016, 174, 1-4.	2.2	3
30	Mast Cell Regulatory Gene Variants Are Common in Mast Cell Activation Syndrome. Blood, 2016, 128, 4878-4878.	0.6	3
31	Characterization of Mast Cell Activation Syndrome. Blood, 2016, 128, 3683-3683.	0.6	1
32	Successful treatment of mast cell activation syndrome with sunitinib. European Journal of Haematology, 2015, 95, 595-597.	1.1	14
33	Mast Cell-Mediated Mechanisms of Nociception. International Journal of Molecular Sciences, 2015, 16, 29069-29092.	1.8	117
34	Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain, Behavior, and Immunity, 2015, 50, 314-321.	2.0	36
35	Mast Cell Activation Disease and Microbiotic Interactions. Clinical Therapeutics, 2015, 37, 941-953.	1.1	19
36	Improving clinical trial accrual by streamlining the referral process. International Journal of Medical Informatics, 2015, 84, 15-23.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Utilities of Various Mast Cell Mediators in Diagnosing Mast Cell Activation Syndrome. <i>Blood</i> , 2015, 126, 5174-5174.	0.6	1
38	Utility of Continuous Diphenhydramine Infusion in Severe Mast Cell Activation Syndrome. <i>Blood</i> , 2015, 126, 5194-5194.	0.6	4
39	Mast Cell Activation Syndrome as a Significant Comorbidity in Sickle Cell Disease. <i>American Journal of the Medical Sciences</i> , 2014, 348, 460-464.	0.4	13
40	A concise, practical guide to diagnostic assessment for mast cell activation disease. <i>World Journal of Hematology</i> , 2014, 3, 1.	0.1	33
41	Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome. <i>Oncology</i> , 2014, 28, 129-31, 134.	0.4	3
42	Utility of hydroxyurea in mast cell activation syndrome. <i>Experimental Hematology and Oncology</i> , 2013, 2, 28.	2.0	13
43	Characterization Of Common Blood Test Abnormalities Potentially Aiding Diagnosis Of Mast Cell Activation Syndrome: A Preliminary Analysis. <i>Blood</i> , 2013, 122, 5240-5240.	0.6	3
44	Sclerosing mediastinitis and mast cell activation syndrome. <i>Pathology Research and Practice</i> , 2012, 208, 181-185.	1.0	13
45	Mast Cell Activation Syndrome Masquerading as Agranulocytosis. <i>Military Medicine</i> , 2012, 177, 113-117.	0.4	10
46	Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts ($50 \times 10^9 - 109/L$): A Comparison to Patients with Normal or High Starting Platelet Counts. <i>Blood</i> , 2012, 120, 176-176.	0.6	7
47	Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3933-3933.	0.6	2
48	Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of $50 \times 10^9 ⁹/L$. <i>Journal of Clinical Oncology</i> , 2012, 30, 6630-6630.	0.8	7
49	Burning mouth syndrome and mast cell activation disorder. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2011, 111, 465-472.	1.6	12
50	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. <i>Clinical Transplantation</i> , 2011, 25, E271-E275.	0.8	5
51	Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. <i>Journal of Hematology and Oncology</i> , 2011, 4, 10.	6.9	107
52	Polycythemia From Mast Cell Activation Syndrome: Lessons Learned. <i>American Journal of the Medical Sciences</i> , 2011, 342, 44-49.	0.4	17
53	Mast cell activation disorder masquerading as pure red cell aplasia. <i>International Journal of Hematology</i> , 2010, 91, 907-908.	0.7	9
54	Fatal Copper Deficiency From Excessive Use of Zinc-Based Denture Adhesive. <i>American Journal of the Medical Sciences</i> , 2010, 340, 164-168.	0.4	26

#	ARTICLE	IF	CITATIONS
55	Support group webcasting: a feasibility assessment. AMIA ... Annual Symposium proceedings, 2005, , 880.	0.2	0
56	General medicine in South Carolina, 1905-2005: the science and the art as recorded in The Journal of the South Carolina Medical Association. The Journal of the South Carolina Medical Association, 2005, 101, 129-36.	0.0	0
57	Leveraging of open EMR architecture for clinical trial accrual. AMIA ... Annual Symposium proceedings, 2003, , 16-20.	0.2	23
58	Web Access to the American Society of Hematology Slide Bank. Blood, 1999, 93, 2425-2426.	0.6	3
59	Web Access to the American Society of Hematology Slide Bank. Blood, 1999, 93, 2425-2426.	0.6	1